FGFR2 and cholangiocarcinoma: However, fibroblast growth factor receptor (FGFR) signalling has emerged as a promising actionable target in CCA following the accelerated approval of FGFR inhibitor, pemigatinib, for patients harbouring FGFR2 fusions and have failed first-line chemotherapy [6].